Display options
Cite
Pattan V, Seth S, Jehangir W, et al. Effect of Atorvastatin and Pioglitazone on Plasma Levels of Adhesion Molecules in Non-Diabetic Patients With Hypertension or Stable Angina or Both. J Clin Med Res. 2015;7(8):613-9doi: 10.14740/jocmr2178e.
Pattan, V., Seth, S., Jehangir, W., Bhargava, B., & Maulik, S. K. (2015). Effect of Atorvastatin and Pioglitazone on Plasma Levels of Adhesion Molecules in Non-Diabetic Patients With Hypertension or Stable Angina or Both. Journal of clinical medicine research, 7(8), 613-9. https://doi.org/10.14740/jocmr2178e
Pattan, Vishwanath, et al. "Effect of Atorvastatin and Pioglitazone on Plasma Levels of Adhesion Molecules in Non-Diabetic Patients With Hypertension or Stable Angina or Both." Journal of clinical medicine research vol. 7,8 (2015): 613-9. doi: https://doi.org/10.14740/jocmr2178e
Pattan V, Seth S, Jehangir W, Bhargava B, Maulik SK. Effect of Atorvastatin and Pioglitazone on Plasma Levels of Adhesion Molecules in Non-Diabetic Patients With Hypertension or Stable Angina or Both. J Clin Med Res. 2015 Aug;7(8):613-9. doi: 10.14740/jocmr2178e. Epub 2015 Jun 09. PMID: 26124907; PMCID: PMC4471748.
Copy Download .nbib Format: NLM
Share it on

J Clin Med Res. 2015 Aug;7(8):613-9. doi: 10.14740/jocmr2178e. Epub 2015 Jun 09.

Effect of Atorvastatin and Pioglitazone on Plasma Levels of Adhesion Molecules in Non-Diabetic Patients With Hypertension or Stable Angina or Both.

Journal of clinical medicine research

Vishwanath Pattan, Sandeep Seth, Waqas Jehangir, Balram Bhargava, Subir Kumar Maulik

Affiliations

  1. Department of Pharmacology, All India Institute of Medical Sciences, New Delhi, India.
  2. Department of Cardiology, All India Institute of Medical Sciences, New Delhi, India.
  3. Raritan Bay Medical Center, Perth Amboy, NJ 08861, USA.

PMID: 26124907 PMCID: PMC4471748 DOI: 10.14740/jocmr2178e

Abstract

BACKGROUND: It was to study the effect of atorvastatin, pioglitazone and their combination on plasma levels of adhesion molecules in patients with hypertension or stable angina or both.

METHODS: It was an open-label, randomized parallel-group study. Forty-five atorvastatin-naive patients with hypertension or stable angina or both, were randomized to receive either atorvastatin (19 patients; 10 mg OD for 12 weeks) or pioglitazone (26 patients; 30 mg OD for 12 weeks). Another group of 30 patients who were already on atorvastatin were put on add-on pioglitazone therapy (pioglitazone (15 mg OD) + atorvastatin (10 mg OD) for 12 weeks). Plasma high-sensitivity C-reactive protein (hsCRP), soluble intercellular adhesion molecule-1 (sICAM-1) and soluble vascular cell adhesion molecule-1 (sVCAM-1) levels were measured at baseline and after 12 weeks of therapy.

RESULTS: Atorvastatin monotherapy significantly reduced plasma sICAM-1, but pioglitazone monotherapy did not produce any significant effect. Addition of pioglitazone in patients already receiving atorvastatin also significantly reduced plasma sICAM-1 level. However, there was no significant change in plasma hsCRP and sVCAM-1 levels in any of the groups after 12 weeks of therapy.

CONCLUSION: There is therapeutic advantage of combining pioglitazone and atorvastatin on plasma sICAM-1 levels.

Keywords: Atorvastatin; Pioglitazone; hsCRP; sICAM-1; sVCAM-1

References

  1. Cardiovasc Drugs Ther. 2006 Feb;20(1):37-44 - PubMed
  2. JAMA. 2003 Sep 10;290(10):1312; author reply 1314-5 - PubMed
  3. Diabetes Care. 2001 Feb;24(2):392-7 - PubMed
  4. Pharmacol Rep. 2009 Jan-Feb;61(1):22-32 - PubMed
  5. Metabolism. 2007 Apr;56(4):559-64 - PubMed
  6. FEBS Lett. 2007 Feb 6;581(3):427-32 - PubMed
  7. J Pediatr Endocrinol Metab. 2007 Oct;20(10 ):1125-36 - PubMed
  8. Endocr Pract. 2007 Mar-Apr;13(2):147-52 - PubMed
  9. Immunol Cell Biol. 2002 Dec;80(6):531-6 - PubMed
  10. Eur Heart J. 2001 Jul;22(14):1226-34 - PubMed
  11. Int J Clin Pharmacol Ther. 2009 May;47(5):311-20 - PubMed
  12. Circulation. 1997 Dec 16;96(12 ):4219-25 - PubMed
  13. J Cardiovasc Pharmacol. 2008 May;51(5):492-504 - PubMed
  14. Circulation. 2006 Jul 18;114(3):184-6 - PubMed
  15. Clin Res Cardiol. 2008 Oct;97(10):726-33 - PubMed
  16. Arthritis Rheum. 2006 Feb;54(2):393-407 - PubMed
  17. N Engl J Med. 2005 Jan 6;352(1):29-38 - PubMed
  18. Vascul Pharmacol. 2006 Jul;45(1):3-18 - PubMed
  19. Horm Metab Res. 2003 Aug;35(8):479-85 - PubMed
  20. Ann Intern Med. 2006 Jul 4;145(1):70-2 - PubMed
  21. Vasc Health Risk Manag. 2007;3(4):355-70 - PubMed
  22. Clin Biochem. 2008 Feb;41(3):126-33 - PubMed
  23. Atherosclerosis. 2003 Sep;170(1):169-76 - PubMed
  24. Lancet. 1998 Jan 10;351(9096):88-92 - PubMed
  25. Heart. 2001 Jun;85(6):623-7 - PubMed
  26. Arterioscler Thromb Vasc Biol. 2003 Feb 1;23(2):283-8 - PubMed
  27. Ann Med. 2003;35(6):398-403 - PubMed
  28. J Am Coll Cardiol. 2006 Oct 17;48(8):1560-6 - PubMed
  29. J Am Coll Cardiol. 2008 Feb 19;51(7):742-9 - PubMed
  30. Nature. 1998 Jan 1;391(6662):79-82 - PubMed
  31. Circulation. 2004 Jun 15;109(23 Suppl 1):III39-43 - PubMed
  32. Cell Adh Migr. 2007 Oct-Dec;1(4):171-5 - PubMed
  33. Cardiology. 2007;108(3):164-9 - PubMed
  34. J Am Coll Cardiol. 2007 Jan 23;49(3):290-7 - PubMed
  35. Circulation. 2006 Feb 14;113(6):867-75 - PubMed
  36. Diab Vasc Dis Res. 2008 Nov;5(4):298-303 - PubMed

Publication Types